Innate Pharma (IPHA) EBT (2019 - 2025)

Innate Pharma (IPHA) has 7 years of EBT data on file, last reported at -$57.2 million in Q4 2025.

• For the quarter ending Q4 2025, EBT fell 8.28% year-over-year to -$57.2 million; the trailing twelve-month figure through Dec 2025 stood at -$160.9 million (down 84.86% YoY), and the FY2025 full-year result was -$57.2 million, down 8.28% from the prior year.
• EBT for Q4 2025 stood at -$57.2 million, down from -$24.2 million in the prior quarter.
• Across five years, EBT topped out at $7.5 million in Q2 2021 and bottomed at -$57.2 million in Q4 2025.
• The 5-year median for EBT is -$24.2 million (2025), against an average of -$23.7 million.
• The widest annual swing landed in 2021, when EBT jumped 166.11%; it then tumbled 13670.83% in 2023.
• A 5-year view of EBT shows it stood at -$52.0 million in 2021, then surged by 99.89% to -$59145.8 in 2022, then sank by 13670.83% to -$8.1 million in 2023, then slumped by 549.05% to -$52.9 million in 2024, then slipped by 8.28% to -$57.2 million in 2025.
• The last three EBT figures came in at -$57.2 million (Q4 2025), -$24.2 million (Q2 2025), and -$52.9 million (Q4 2024), per Business Quant data.

Peer Comparison